The goal of the Career Development Program is to prepare physicians and scientists for independent careers in translational research in sarcoma. It is our hope that the women and men funded through this process will spend their professional lifetimes conducting translational research specifically in this set of diseases and that they will become leaders in their fields of interest. Memorial Sloan-Kettering Cancer Center (MSKCC) is ideally suited for this task, with substantial physical and faculty resources and more than a century of experience training physicians and scientists of the highest quality. Our institutional environment includes a K12 for translational science training and a K30 for the training of clinical investigators. In the Career Development Program, we plan to enhance the formal training programs that already exist at MSKCC. We will encourage more physicians to focus on translational research in sarcoma and will similarly strive to attract basic scientists to devote postdoctoral fellowship training to this quickly evolving field. We will also provide partial support for two new junior faculty investigators every 2 to 3 years who commit their careers to translational research in sarcoma. In our efforts to recruit these investigators, we will draw upon existing programs at MSKCC that recruit, train, and mentor postgraduate scientists and physician-scientists. We will budget at least $150,000 yearly for this program, including $50,000 from the SPORE award itself and at least $100,000 in funds pledged by MSKCC. To continually educate both trainees and SPORE staff, we will utilize regularly scheduled conferences, data presentations by members of the SPORE research projects and cores, and presentations by invited speakers. The Career Development Program will be directed by a Career Development Committee, chaired by Dr. David Spriggs and Dr. Robert Maki.
| Dickson, Brendan C; Antonescu, Cristina R; Argyris, Prokopios P et al. (2018) Ectomesenchymal Chondromyxoid Tumor: A Neoplasm Characterized by Recurrent RREB1-MKL2 Fusions. Am J Surg Pathol 42:1297-1305 |
| Weinreb, Ilan; Bishop, Justin A; Chiosea, Simion I et al. (2018) Recurrent RET Gene Rearrangements in Intraductal Carcinomas of Salivary Gland. Am J Surg Pathol 42:442-452 |
| Kao, Yu-Chien; Flucke, Uta; Eijkelenboom, Astrid et al. (2018) Novel EWSR1-SMAD3 Gene Fusions in a Group of Acral Fibroblastic Spindle Cell Neoplasms. Am J Surg Pathol 42:522-528 |
| Bartenstein, Diana W; Coe, Taylor M; Gordon, Samantha C et al. (2018) Lipofibromatosis-like neural tumor: Case report of a unique infantile presentation. JAAD Case Rep 4:185-188 |
| Chen, Yu; Chi, Ping (2018) Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers. J Hematol Oncol 11:78 |
| Owosho, Adepitan A; Estilo, Cherry L; Huryn, Joseph M et al. (2018) A Clinicopathologic Study of Head and Neck Malignant Peripheral Nerve Sheath Tumors. Head Neck Pathol 12:151-159 |
| Dickson, Brendan C; Sung, Yun-Shao; Rosenblum, Marc K et al. (2018) NUTM1 Gene Fusions Characterize a Subset of Undifferentiated Soft Tissue and Visceral Tumors. Am J Surg Pathol 42:636-645 |
| Ran, Leili; Chen, Yuedan; Sher, Jessica et al. (2018) FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal Tumor. Cancer Discov 8:234-251 |
| Klein, Mary E; Dickson, Mark A; Antonescu, Cristina et al. (2018) PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence. Oncogene 37:5066-5078 |
| Banito, Ana; Li, Xiang; Laporte, Aimée N et al. (2018) The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. Cancer Cell 34:346-348 |
Showing the most recent 10 out of 169 publications
